Intro Pullout Text Widget

Journal of Neurology, Neurosurgery and Psychiatry

is a leading international journal publishing the latest research and reviews on all areas of neurological sciences.
Impact Factor: 13.654
All metrics >>

Journal of Neurology, Neurosurgery and Psychiatry is a Plan S compliant Transformative Journal.

Journal of Neurology, Neurosurgery and Psychiatry (JNNP)'s ambition is to publish the most ground-breaking and cutting-edge research from around the world. Encompassing the entire genre of neurological sciences, our focus is on the common disorders (stroke, multiple sclerosis, Parkinson's disease, epilepsy, peripheral neuropathy, subarachnoid haemorrhage and neuropsychiatry), but with a keen interest in the Gordian knots that present themselves in the field, such as ALS. With early online publication, regular podcasts and an immense archive collection (with the longest half-life of any journal in clinical neuroscience), JNNP is a trail-blazer and not a follower.

Subscribers to JNNP also have access to Practical Neurology and the Journal of NeuroInterventional Surgery.

Podcast iconJNNP publishes regular podcasts discussing highlights from its issues. Subscribe in all podcast platforms, including Apple Podcasts, Google Podcasts, Stitcher and Spotify.

Editor in Chief: We are pleased to announce Dr Karen Furie as the new Editor-in-Chief of Journal of Neurology, Neurosurgery & Psychiatry.
Editorial Board

Latest Content


JNNP accepts submissions of a wide range of article types, including review articles and original research.
The Author Information section provides specific article requirements to help you turn your research into an article suitable for JNNP.
Information is also provided on editorial policies and open access.



Featured Video

Cognitive and neuropsychiatric effects of noradrenergic treatment in Alzheimer’s disease

To cite: David MCB, Del Giovane M, Liu KY, et al. Cognitive and neuropsychiatric effects of noradrenergic treatment in Alzheimer’s disease: systematic review and meta-analysis. Journal of Neurology, Neurosurgery & Psychiatry Published Online First: 05 July 2022. doi: 10.1136/jnnp-2022-329136
Read the full article here: linkObjective: To assess the efficacy of drugs with principally noradrenergic action in improving cognitive and europsychiatric symptoms in Alzheimer’s disease.
Conclusions: Repurposing of established noradrenergic drugs is most likely to offer effective treatment in Alzheimer’s disease for general cognition and apathy. However, several factors should be considered before designing future clinical trials. These include targeting of appropriate patient subgroups and understanding the dose effects of individual drugs and their interactions with other treatments to minimise risks and maximise therapeutic effects.